These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 22576692

  • 1. The receptor tyrosine kinase inhibitor vandetanib activates Akt and increases side population in a salivary gland tumor cell line (A253).
    Fujishiro Y, Tonogi M, Ochiai H, Matsuzaka K, Yamane GY, Azuma T.
    Int J Oncol; 2012 Jul; 41(1):362-8. PubMed ID: 22576692
    [Abstract] [Full Text] [Related]

  • 2. Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach.
    Lange F, Rateitschak K, Kossow C, Wolkenhauer O, Jaster R.
    World J Gastroenterol; 2012 Nov 21; 18(43):6226-34. PubMed ID: 23180942
    [Abstract] [Full Text] [Related]

  • 3. EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer.
    Singh S, Trevino J, Bora-Singhal N, Coppola D, Haura E, Altiok S, Chellappan SP.
    Mol Cancer; 2012 Sep 25; 11():73. PubMed ID: 23009336
    [Abstract] [Full Text] [Related]

  • 4. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
    Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, Melisi D, De Vita F, De Placido S, Bianco AR, Tortora G.
    Clin Cancer Res; 2004 Jan 15; 10(2):784-93. PubMed ID: 14760102
    [Abstract] [Full Text] [Related]

  • 5. Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo.
    Ferrari SM, Bocci G, Di Desidero T, Ruffilli I, Elia G, Ragusa F, Fioravanti A, Orlandi P, Paparo SR, Patrizio A, Piaggi S, La Motta C, Ulisse S, Baldini E, Materazzi G, Miccoli P, Antonelli A, Fallahi P.
    Oncol Rep; 2018 May 15; 39(5):2306-2314. PubMed ID: 29517106
    [Abstract] [Full Text] [Related]

  • 6. Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors.
    Griffero F, Daga A, Marubbi D, Capra MC, Melotti A, Pattarozzi A, Gatti M, Bajetto A, Porcile C, Barbieri F, Favoni RE, Lo Casto M, Zona G, Spaziante R, Florio T, Corte G.
    J Biol Chem; 2009 Mar 13; 284(11):7138-48. PubMed ID: 19147502
    [Abstract] [Full Text] [Related]

  • 7. Cancer stem-like cell properties are regulated by EGFR/AKT/β-catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma.
    Ma L, Zhang G, Miao XB, Deng XB, Wu Y, Liu Y, Jin ZR, Li XQ, Liu QZ, Sun DX, Testa JR, Yao KT, Xiao GH.
    FEBS J; 2013 May 13; 280(9):2027-41. PubMed ID: 23461856
    [Abstract] [Full Text] [Related]

  • 8. Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells.
    Cascone T, Morelli MP, Morgillo F, Kim WY, Rodolico G, Pepe S, Tortora G, Berrino L, Lee HY, Heymach JV, Ciardiello F.
    J Cell Physiol; 2008 Sep 13; 216(3):698-707. PubMed ID: 18381602
    [Abstract] [Full Text] [Related]

  • 9. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.
    Ono M, Hirata A, Kometani T, Miyagawa M, Ueda S, Kinoshita H, Fujii T, Kuwano M.
    Mol Cancer Ther; 2004 Apr 13; 3(4):465-72. PubMed ID: 15078990
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
    Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, Lifshits E, Byers LA, Xu L, Wu HK, Jänne P, Kobayashi S, Halmos B, Tenen D, Tang XM, Engelman J, Yeap B, Folkman J, Johnson BE, Heymach JV.
    Clin Cancer Res; 2009 May 15; 15(10):3484-94. PubMed ID: 19447865
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.
    Lyros O, Mueller A, Heidel F, Schimanski CC, Gockel I, Galle PR, Lang H, Moehler M.
    Int J Cancer; 2010 Sep 01; 127(5):1197-208. PubMed ID: 20039326
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line.
    Lee YY, Kim HP, Kang MJ, Cho BK, Han SW, Kim TY, Yi EC.
    Exp Mol Med; 2013 Nov 22; 45(11):e64. PubMed ID: 24263233
    [Abstract] [Full Text] [Related]

  • 17. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
    Thomson S, Petti F, Sujka-Kwok I, Epstein D, Haley JD.
    Clin Exp Metastasis; 2008 Nov 22; 25(8):843-54. PubMed ID: 18696232
    [Abstract] [Full Text] [Related]

  • 18. Boolean ErbB network reconstructions and perturbation simulations reveal individual drug response in different breast cancer cell lines.
    von der Heyde S, Bender C, Henjes F, Sonntag J, Korf U, Beißbarth T.
    BMC Syst Biol; 2014 Jun 25; 8():75. PubMed ID: 24970389
    [Abstract] [Full Text] [Related]

  • 19. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.
    Chen CT, Kim H, Liska D, Gao S, Christensen JG, Weiser MR.
    Mol Cancer Ther; 2012 Mar 25; 11(3):660-9. PubMed ID: 22238368
    [Abstract] [Full Text] [Related]

  • 20. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B, Chang CM, Yuan M, McKenna WG, Shu HK.
    Cancer Res; 2003 Nov 01; 63(21):7443-50. PubMed ID: 14612544
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.